Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Regeneron

How Is Regeneron Pharmaceuticals' Stock Performance Compared to Other Biotechnology Stocks?

Regeneron Pharmaceuticals has outperformed the broader market over the past year, and Wall Street analysts are optimistic about the stock’s outlook.

Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms

Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms

Regeneron stock jumped early Thursday, bolstered by strong sales of a high-dose version of its blockbuster eye disease treatment, Eylea.

Investors Business Daily

Regeneron To Defend Against DOJ Complaint On Drug Pricing

Regeneron To Defend Against DOJ Complaint On Drug Pricing

Regeneron faces DOJ legal challenge over drug-price manipulation allegations, vows to defend itself. Case could impact pharmaceutical industry and drug pri...

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Are Regeneron's Legal Troubles — And Six-Week Slide — A Buying Opportunity?

Regeneron stock toppled Thursday after the DOJ filed a lawsuit saying the drugmaker fraudulently inflated the prices of its drug, Eylea.

Investors Business Daily

US Appeals Court Revives Regeneron Antitrust Lawsuit Against Novartis

U.S. appeals court revives Regeneron's antitrust lawsuit against Novartis, highlighting alleged anticompetitive behavior.

Plunge into Profits With These 3 Biotech Stocks

The biotech industry's robust growth potential is driven by substantial pharma research and development, swift technological advancements, and lucrative government support. Given this backdrop, quality biotech stocks ProQR Therapeutics N.V. (PRQR), Regeneron Pharmaceuticals (REGN), and Corcept Therapeutics (CORT) could be solid buys now. Read on….

The Surprising Sources Of Regeneron's Fourth-Quarter Beat As Shares Hit Another Record High

Regeneron Pharmaceuticals put up a commanding fourth-quarter beat on Friday, helped by Praluent. REGN stock is trading at an all-time high.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Regeneron surpasses Q4 revenue expectations with strong results

Regeneron surpasses Q4 revenue expectations with strong results

Regeneron Pharmaceuticals surpasses expectations with strong fourth-quarter revenue, boosting investor confidence in the company's performance.

Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again

Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again

There's more than Eylea to like about Regeneron Pharmaceuticals right now, an analyst said Friday as REGN stock touched another record high.

Investors Business Daily

Regeneron Slumps As Its Biggest Moneymaker Flops Amid Ongoing Roche Rivalry

Regeneron Slumps As Its Biggest Moneymaker Flops Amid Ongoing Roche Rivalry

Regeneron preannounced disappointing U.S. Eylea sales, while Exelixis issued light 2024 guidance. REGN stock and EXEL stock slumped.

Investors Business Daily

Eylea Sales Soar, Regeneron Breaks Records with Eylea Sales Soar, Regeneron Breaks Records with Top News.34 Billion!.34 Billion!

Eylea Sales Soar, Regeneron Breaks Records with Eylea Sales Soar, Regeneron Breaks Records with Top News.34 Billion!.34 Billion!

Regeneron's Q4 sales of Eylea skyrocketed to a staggering Eylea Sales Soar, Regeneron Breaks Records with Top News.34 Billion!.34 billion in the U.S., sending shockwaves through the pharmaceutical industry. Incredible suc...

Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales

Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales

Regeneron and Sanofi said Monday their blockbuster drug, Dupixent, significantly improved symptoms COPD symptoms.

Investors Business Daily

Regeneron Jumps On Third-Quarter Beat As High-Dose Eylea Delivers

Regeneron Jumps On Third-Quarter Beat As High-Dose Eylea Delivers

Regeneron Pharmaceuticals topped third-quarter forecasts on Thursday, helped by a strong launch from its high dose of Eylea. REGN stock rose.

Investors Business Daily

Regeneron Pharmaceuticals (REGN) Earnings Analysis -- Should Investors Brace for Impact?

Regeneron Pharmaceuticals (REGN) Earnings Analysis -- Should Investors Brace for Impact?

Regeneron Pharmaceuticals (REGN) has an impressive revenue and earnings surprise history. So, as the company gears up to post its third-quarter report, is REGN the right pick? Read on.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Slides 200 Points After Market Sell-Off; Tesla Stock Skids To Key Level

The Dow Jones dropped 200 points Friday after Thursday's stock market sell-off. Tesla stock sold off Friday, hitting a key level.

Investors Business Daily

Dow Jones Slides After Surprise Jobless Claims; Tesla Dives On Elon Musk Cybertruck Warning

The Dow Jones dropped Thursday after surprise initial unemployment claims. Tesla stock dived on Elon Musk's Cybertruck warning.

Investors Business Daily

Dow Jones Falls After Key Housing Data; Tesla Stock Slides Ahead Of Earnings

The Dow Jones Industrial Average dropped Wednesday after key housing data. Netflix and Tesla earnings are due out after the close.

Investors Business Daily

Dow Jones Drops After Strong Retail Sales; Tesla Stock Slides On Recall; Nvidia Dives On AI Chip Ban

The Dow Jones dropped Tuesday after strong U.S. retail sales data. Tesla stock fell after recalling nearly 55,000 vehicles.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Rallies 300 Points As Market Rally Snaps Back; Netflix, Nvidia, Tesla In Focus

Dow Jones futures were lower Tuesday after the Dow Jones industrials rallied than 300 points Monday. Netflix, Nvidia and Tesla are in focus.

Investors Business Daily

Dow Jones Rallies 250 Points As Netflix, Tesla Earnings Loom; Apple Falls On iPhone 15 News

The Dow Jones rose Monday as Netflix and Tesla earnings loom this week. Apple stock dropped on iPhone 15 news.

Investors Business Daily

Regeneron Bulls, Bears Clash: Will Biotech Get Eylea Mojo Back?

With Regeneron earnings due Nov. 2, the big debate is whether the company will get its mojo back in its core eye disease treatment business?

How to Enhance Your Own Strategies with POWR Ratings

Wall Street is never lacking in strategy or trading ideas. In investing, if you can combine two or more strategies that align around a particular investing idea, you can enhance your likelihood of success. This idea combines our POWR Ratings with a strategy that is currently making the rounds on…

Investors Keeping a Close Eye on These 3 Biotech Stocks

Growing adoption of AI technologies by biopharmaceutical companies and growing foothold of personalized medicine are expected to drive growth in the biotech market. Therefore, it could be wise to buy fundamentally strong biotech stocks Regeneron Pharmaceuticals (REGN), Corcept Therapeutics (CORT), and Incyte (INCY). Read more.

3 Biotechs with Massive Growth Potential

These three biotech stocks have massive growth opportunities on the horizon, and could add a huge boost to any portfolio. They play in some of the most in demand markets on the planet, and have track records of finding ways to introduce products into those markets to capture big profits.…

3 Biotech Gainers to Consider

Robust demand, technological advancements, government and private investment, are fueling the biotech industry’s expansion and driving game-changing therapies and product development. With the industry anticipated to thrive, fundamentally strong biotech stocks Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and United Therapeutics (UTHR) look poised for substantial gains. Keep reading.

People

Steven AdamsAfter

Christopher Raymond

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Bank of America

United Airlines

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

256,319 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play